Anti-PF4 antibodies: VITT, HIT, and other disorders

2021-09-27

Ted Warkentin, Ishac Nazy, Donald M. Arnold, Nadia Gabarin, Sarah E. Patterson, Karen Moffat

Dr Ted Warkentin, Dr Ishac Nazy, Dr Donald M. Arnold, Dr Nadia Gabarin, and Dr Sarah E. Patterson joined Dr Karen Moffat to discuss anti–platelet factor 4 (PF4) antibody–related disorders at the McMaster Chair's Medical Grand Rounds on September 17, 2021.

See also

The 3 most important recent advances in the management of venous thrombosis Dr James Douketis from McMaster University shares his views on the 3 most important recent advances in the management of venous thrombosis.
What's new with COVID-19? Dr Zain Chagla and Dr Dominik Mertz from McMaster University present the most current data on COVID-19 during the Chair's Medical Grand Rounds, Town Hall.
Updates in Hematology A number of textbook chapters in Hematology have been recently updated online and in mobile apps.
To anticoagulate or not to anticoagulate? Part 2 Dr Ryan Zarychanski from University of Manitoba, Canada, joins Dr Roman Jaeschke to discuss the latest trial results regarding anticoagulation in noncritically ill patients with COVID-19.
To anticoagulate or not to anticoagulate? Part 1 Dr Ryan Zarychanski from University of Manitoba, Canada, joins Dr Roman Jaeschke to discuss the latest trial results regarding anticoagulation in critically ill patients with COVID-19.
Publications of the Week, August 19 A digest of noteworthy publications curated by editors from McMaster University. This week’s focus: anticoagulation in critically and noncritically ill patients with COVID-19.
COVID-19 vs thrombosis: Who should receive anticoagulation? Dr Roman Jaeschke, an intensivist, and Dr James Douketis, an expert in thrombosis, discuss the paradigm-changing results of the latest clinical trials on therapeutic anticoagulation in patients with COVID-19.
The 3 most important recent advances in treating pulmonary embolism Dr Adam Torbicki, professor of medicine at Center of Postgraduate Medical Education in Warsaw, Poland, presents the 3 most recent advances in treating pulmonary embolism.
The 3 most important recent advances in the management of nonmalignant blood diseases Dr Mark Crowther from McMaster University shares his views on the 3 most important recent advances in the management of nonmalignant blood diseases.

Anti-PF4 antibodies: VITT, HIT, and other disorders

Social Media